
Work Here?
RA Capital Management channels capital and expertise into healthcare, life sciences, and planetary health companies across growth stages. It funds ventures from private seed rounds to public follow-ons and uses evidence-based investing to guide decisions. Its TechAtlas research engine and Raven incubator provide internal data and a collaborative platform for entrepreneurs to develop and commercialize ideas. The firm aims to grow value for its portfolio and stakeholders by supporting companies that advance health outcomes, managing over $10 billion in assets.
Industries
Financial Services
Healthcare
Company Size
N/A
Company Stage
N/A
Total Funding
$39.4B
Headquarters
Boston, Massachusetts
Founded
2001
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$39.4B
Above
Industry Average
Funded Over
0 Rounds
Remote Work Options
Flexible Work Hours
Professional Development Budget
Infinimmune has raised $75 million in a series A funding round led by Regeneron Ventures. The company develops antibody discovery technology. The startup plans to use the capital to advance its antibody discovery platform. Regeneron's venture arm headlined the investment round.
Plantible Foods has raised $35 million in USDA-backed financing to expand production of its duckweed-derived Rubisco protein. The San Diego startup secured $25 million in debt from X-Caliber Rural Capital, a USDA-licensed lender, plus $10 million in equity from RA Capital and existing investors including Piva Capital. The funding will finance up to 50 new greenhouses at Plantible's 100-acre Texas facility, increasing capacity fivefold to over 100,000 tonnes annually. The company's Rubi Protein ingredient, which received FDA clearance six months ago, offers functional properties matching egg whites whilst delivering a 70% nutritional yield. Duckweed grows in two to three days with minimal water use and contains all nine essential amino acids. Plantible has raised $92 million to date.
Expedition Therapeutics has closed an oversubscribed $115 million series B funding round to advance its lead DPP1 inhibitor into phase 2 trials for chronic obstructive pulmonary disease (COPD). The financing attracted a roster of prominent investors. The company is developing a DPP1 inhibitor, a drug class that targets a specific enzyme involved in inflammatory diseases. The series B proceeds will support clinical development of Expedition's lead candidate as it progresses through mid-stage trials. Expedition is backed by Sanofi, though the pharmaceutical giant's participation in this particular funding round was not specified in the available information.
Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Capital...
Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class...
Find jobs on Simplify and start your career today
Industries
Financial Services
Healthcare
Company Size
N/A
Company Stage
N/A
Total Funding
$39.4B
Headquarters
Boston, Massachusetts
Founded
2001
Find jobs on Simplify and start your career today